Related Experiment Videos
Tardive dyskinesia in northern Israel: preliminary study
1Department of Neurology, Faculty of Medicine, Bnai Zion Medical Center, Acre, Israel.
European Neurology
|January 1, 1993
Summary
Tardive dyskinesia (TD) affects 20% of patients on long-term neuroleptic treatment, with higher rates in females and older individuals. Electroconvulsive therapy may reduce TD prevalence in males.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Tardive dyskinesia (TD) is a neurological disorder resulting from long-term use of neuroleptic medications.
- It is characterized by involuntary movements, primarily in the orofacial region, but can also affect extremities, head, and trunk.
Purpose of the Study:
- To investigate the prevalence of tardive dyskinesia in patients undergoing chronic neuroleptic treatment.
- To identify demographic and clinical factors associated with TD development.
Main Methods:
- Cross-sectional study of patients receiving chronic neuroleptic therapy.
- Assessment of TD prevalence based on patient demographics and treatment history.
- Analysis of the impact of electroconvulsive therapy (ECT) on TD incidence in males.
Main Results:
- Overall TD prevalence was 20% in the studied population.
- Females exhibited a significantly higher prevalence of TD (27%) compared to males.
- Older patients and those with a history of seizures showed varying associations with TD, with all seizure patients with TD being female.
Conclusions:
- Chronic neuroleptic treatment is associated with a substantial risk of developing tardive dyskinesia.
- Female sex and older age are identified as risk factors for TD.
- Electroconvulsive therapy may have a protective effect against TD in male patients.